Audit: QRS - Horny Goat Weed for Health & Longevity

Audit conducted on 21/09/2026 08:44 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to the ER: protocol doses to ER 366/368/376, time-to-effect to ER 423/165/171-173, benefit and risk tier items to the ER Expected Benefits and Potential Risks & Side Effects headings, all ten markers and their targets/rationales to the ER biomarker table (ER 459-468), cadence to ER 455, qualitative items to ER 472-479.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“has no controlled human study” mirrors ER 503; “the unproven androgen claim” (marker_9_why) is verbatim ER 467; “one unreplicated combination-mixture trial” preserves ER 171; “in the only controlled trial” preserves ER 423.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications stay absolute (“Pregnancy and breastfeeding at any stage”); interactions stay as cautions; speculative benefits stay in the Speculative tier.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	stop_items come only from the ER “Populations who should avoid Horny Goat Weed” list (ER 333-342); caution_items only from the ER interaction bullets (ER 303-329). No Benefit-Modifying or Risk-Modifying Factor is surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names appear. The only study references (“the 24-month trial regimen”, “the 2025 case report”, “the only controlled trial”) are ER wording for the same facts.
1.6	The QRS does not introduce new attributions.	🟢	No attribution is added; the ER’s “Chinese University of Hong Kong … led by Qin and Zhang” is reduced to “the 24-month trial regimen” rather than replaced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The measured, evidence-weighing register of the ER Conclusion carries through to the lede and the tier lists.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tier labels, quantified targets and explicit evidence qualifiers give the reader the basis to decide rather than a verdict.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	No imperatives; monitoring and protocol content is stated as observed practice and trial regimen.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend” or “advise” anywhere in the body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Cadence and protocol cells are declarative statements of what was done or measured.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns in the rendered body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical shorthand appears only where the ER itself requires it (CTX/P1NP are expanded in the same row’s marker name); the lede is fully lay.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate, tier and table cell is a stripped noun phrase; no sentences of explanation survive.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the body.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Ten-marker laboratory panel, functional (not conventional) reference ranges and a detailed contraindication gate presuppose exactly this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-weekly blood pressure self-measurement, 3-6 month turnover markers and 12-24 month density scans are presented without hedging about burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification to a consumer “how to take it” summary; the sheet leads with evidence strength and gates.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede makes the central asymmetry explicit — strong for bone, absent for the sexual-function use most buyers want — and the product-adulteration risk is raised to its own Medium tier entry.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; benefits_speculative uses “slowed cellular aging and extended lifespan”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No “pill”, “shot” or “taken by mouth”; route is given as “with meals”. Plain-language equivalents in the lede (“disturbed heart rhythm”, “muscle damage”) are the ER Conclusion’s own wording (ER 505).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte (QRS lines 440, 477, 519, 539, 556, 580, 599, 603-605, 729 and the four tier labels in each of the Benefits and Risks lists).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 singleton variables present, plus the repeatable marker_#name/target/why (×10) and qualitative_item# (×8) rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template returns no differences outside the variable regions; the three website= spans (evidence_review, audit, full_review) and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section feeding the QRS is empty; all four benefit tiers, all four risk tiers, the contraindication list, the interaction list and the biomarker table are populated.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Bone protocol dose”, action_2_label “Supplement-market dose” and action_3_label “Best time of day” are the ER’s bold labels verbatim (ER 366, 368, 376).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect and marker labels likewise track the ER headings and biomarker names without paraphrase.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	A character scan of the rendered body returns no emoji; the ER’s tier emoji and the “⚠️ Conflicted” marker on the High benefit are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to the minimum the per-section rules permit — gate items carry only the key fact plus the mandated parentheticals (8.5/9.5), tier items are stripped noun phrases, and the biomarker and qualitative lists are the complete sets that 14.2/15.2 require.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	QRS lines 2-14; the comment opens on line 2, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It sits inside an HTML comment and no element on the sheet repeats any of its values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: horny_goat_weed_2026-0921-0530_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0921-0838, in the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no context-window or other qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name, horny_goat_weed_2026-0921-0530_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eight keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Horny Goat Weed for Health & Longevity - Quick Reference Sheet”; the ampersand is entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Horny Goat Weed for Health & Longevity”, matching canonical_topic at ER line 8.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/21/2026”, the correct reformatting of 2026-0921-0838.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, identical to the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template subline; the ER’s “Also known as” list is not reproduced.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER 503-505 into mechanism, where evidence is strongest, where it is absent, and the two decision-relevant harm classes.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Vasodilation and weak bone estrogenicity ← ER 503; bone density and back pain in postmenopausal women ← ER 503; absent sexual-function trial ← ER 503; scattered liver/rhythm/muscle reports and undeclared drugs ← ER 505.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “disturbed heart rhythm” replaces arrhythmia and “bone density” replaces BMD.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial is named and no year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No percentages, SMDs, odds ratios or confidence intervals.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items come from the “Populations who should avoid Horny Goat Weed” list at ER 331-342, inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All ten ER avoid-list entries are present, in ER order, plus the nitrate entry the ER flags as an “Absolute contraindication” (ER 303).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	QRS lines 542-551: ten discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing clause is stripped: “— no human safety data exist…”, “given the reported hypomania”, “given the platelet signal” and “where nitrates are standard” are all absent. No dashes remain in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Preserved: the four hormone-sensitive cancer sites, “Child-Pugh score of B or C”, “within 90 days”, the two named arrhythmias, “stage 4 or worse (eGFR below 30 mL/min/1.73 m²)”, “Within 14 days” and “under 18”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names ten such populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All twelve items map to the interaction bullets at ER 303-329.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Twelve of the ER’s fourteen interaction bullets appear; the two correctly omitted are nitrates (absolute contraindication, already in stop_items) and buprenorphine/opioid-agonist therapy (already in stop_items).
9.3	Individual [caution_items] are formatted as <li></li>	🟢	QRS lines 559-570: twelve discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution./Monitor.” verdict, consequence sentence and “Mitigation:” clause is stripped, as is the ER’s leading “Other interventions — “ on the final bullet. No dashes remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER drug list is carried, including “acetaminophen at high intake”, “fish oil above 3 g daily” and “high-dose caffeine”; only the glossing phrase “bone-breakdown blockers such as” is trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses; all parentheticals are already plain comma-separated lists.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names fourteen such interactions, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at ER 366, 368 and 376.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The trial-derived bone dose, the market dose range and dose timing are the three bullets that determine what a user actually takes and when; the remaining bullets are modifiers or comparisons.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Protocol section contains eleven bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content: 60 mg icariin with 300 mg elemental calcium, 500-1,000 mg extract at 10-20% icariin, and morning/early-afternoon dosing with the fat-absorption and palpitation rationale from ER 376.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Bone mineral density (ER 423), osteoporosis-related back pain (ER 165) and COPD symptoms at three months (ER 173) are the three outcomes for which the ER states a time course.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER benefit tiers exactly: High (bone density) → Medium (back pain) → Low (COPD).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated: “12-24 months”, “About 11 days sooner” and “3 months”, each with an ER-sourced qualifying sub-line.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (ER 423), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine listed benefits are the ER’s Expected Benefits sub-headings (ER 153-201).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 521-532, matching the ER’s four tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare benefit name; no Magnitude figure, mechanism sentence or “⚠️ Conflicted” qualifier is carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit spans; “(COPD, long-term airway narrowing causing breathlessness)” from ER 171 is correctly dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine listed risks are the ER’s Potential Risks & Side Effects sub-headings (ER 229-279).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 582-593, matching the ER’s four tiers.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare risk name; the pooled RR, the ConsumerLab failure counts and the case-report details stay in the ER.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk spans; the ER’s glosses such as “(dangerously low blood pressure)” and “(CK, an enzyme released when muscle is damaged)” are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence come from the ER Monitoring Protocol & Defining Success section (ER 455-468).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarker-table rows are present, in ER order, with Target and Why columns transcribed verbatim from ER 459-468.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 723 reproduces the ER 455 schedule: liver enzymes and CK at 6-8 weeks / 6 months / every 6-12 months, blood pressure twice weekly for the first fortnight, turnover markers at 3-6 months, density scan no sooner than 12-24 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All eight items come from the “Qualitative markers worth tracking alongside the laboratory values” list at ER 470-479.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All eight ER bullets are present, in ER order and verbatim, at QRS lines 732-754.

Issues 21/09/2026 08:44

Pass rate 100.00%. No issues found.